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Objectives. A cleavage fragment of collagen XVIII, endostatin, is released into the circulation and has been demonstrated to have
antiangiogenic effects in animalmodels.We hypothesized that circulating endostatin would be increased in patients with symptoms
of lower limb peripheral artery disease.Design. Cross-sectional study. Participants. Community dwelling oldermen.Measurements.
Intermittent claudication was defined using the Edinburgh Claudication Questionnaire (ECQ). Serum endostatin was measured
by a commercial ELISA.The association of serum endostatin with intermittent claudication was examined using logistic regression
adjusting for age, diabetes, hypertension, dyslipidemia, coronary heart disease, and stroke. Results. Serum endostatin wasmeasured
in 1114 men who completed the ECQ. 106 men had intermittent claudication, 291 had atypical pain, and 717 had no lower limb pain.
Mean (±standard deviation) serum endostatin concentrations (ng/mL) were 145.22± 106.93 formenwith intermittent claudication,
129.11 ± 79.80 for men with atypical pain, and 116.34 ± 66.57 for men with no lower limb pain; 𝑃 < 0.001. A 70 ng/mL increase in
endostatin was associated with a 1.17-fold rise in the adjusted odds of having intermittent claudication (OR 1.17, 95% confidence
interval 1.00–1.37, and 𝑃 = 0.050). Conclusions. Serum endostatin is raised in older men who have symptoms of intermittent
claudication. The role of endostatin in the genesis and outcome of peripheral artery disease requires further investigation.
1. Introduction
Lower limb ischemia due to atherosclerosis of the peripheral
arteries, commonly termed peripheral artery disease, is a
common problem in older adults worldwide [1–3]. The
symptoms associated with stenosis or occlusion of lower limb
arteries are highly variable [4, 5]. A significant proportion
of patients with lower limb ischemia (defined as ankle
brachial pressure index <0.9) report no leg symptoms [4, 5].
The exact determinants of symptom severity and outcome
for patients with lower limb arterial occlusive disease are
poorly understood but likely depend on the ability of the
limb to adapt to atherosclerosis through development of
new capillaries (angiogenesis) and expansion of collateral
arteries (arteriogenesis) [6]. Currently, however, the factors
determining angiogenesis and arteriogenesis in patients are
poorly defined.
Collagen XVIII is a heparan sulphate proteoglycan
expressed (amongst other sites) within elastic arteries [7,
8]. A C-terminal breakdown product of collagen XVIII,
known as endostatin, has been extensively investigated for its
role in suppression of neoplastic tumours [7]. Both animal
model and in vitro studies suggest that endostatin has anti-
angiogenic effects [9–11]. Recombinant endostatin is being
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Given the likely importance of angiogenesis in determin-
ing the symptoms associated with peripheral artery disease
we hypothesised that circulating endostatin concentrations
would be increased in patients who have intermittent clau-
dication. The aim of this study was to compare serum
concentration of endostatin in patients with and without
intermittent claudication.
2. Methods
2.1. Study Design. To examine the association of serum
endostatin concentration with symptoms of intermittent
claudication we utilized men recruited from the Health in
Men Study (HIMS). HIMS was developed from a community
based trial of screening for abdominal aortic aneurysm
performed between 1996 and 1999 (wave 1) [13]. 4248 men
reattended between 2001 and 2004 and completed a second
questionnaire and had their blood collected (wave 2). For
the current study we randomly selected approximately 25%
of men (𝑛 = 1117) based on previous studies of circulating
endostatin concentration which suggested that this number
of subjects would provide >80% power to detect a 30%
difference between cases and controls [14, 15]. The University
of Western Australia Human Research Ethics Committee
approved the study, and all men gave written informed
consent.
2.2. Risk Factors and Medication. Risk factors were defined
from questionnaires administered at initial assessment (wave
1) and the time of blood sampling (wave 2). Coronary heart
disease (CHD) was recorded in patients with a history of
angina, myocardial infarction, or coronary revascularization.
Hypertension, diabetes, and dyslipidemia were defined by a
past history of diagnosis or treatment for these conditions.
Medications recorded at the time of blood sampling including
lipid modifying medication, antihypertensive medication,
and diabetes medication were used in these definitions. Past
history of stroke was also recorded at both assessments and
used to define previous stroke.
2.3. Definition of Intermittent Claudication. Symptoms of
intermittent claudication were defined by responses to the
Edinburgh Claudication Questionnaire (ECQ) completed at
the time of blood sampling as previously described [15].
The ECQ comprises seven items asking whether pain or
discomfort in the legs is present on walking; the distance
before pain limitswalking;whether pain occurswith standing
still or sitting, whenwalking uphill or hurrying; whether pain
occurs with walking at ordinary pace on level ground; and
whether pain diminishes within 10min of resting. Aman was
classified as positive in the ECQ if he had leg pain when
walking, but not sitting or standing, which was relieved by
standing still for 10min.Where pain was present on standing
or sitting and not relieved by rest for 10mins it was defined as
atypical.
2.4. Measurement of Serum Endostatin. Blood samples were
collected between 08:00 h and 10:30 h. Serum was prepared
immediately following phlebotomy and stored at −80∘C until
assayed. Serum endostatin was measured with a commercial
assay (R&D Systems, Minneapolis, USA) by an experienced
scientist unaware of the case or control status. The intra-
and interassay coefficients of variations were 7.3 and 9.0%,
respectively.
2.5. Statistical Analyses. Quantitative data were not nor-
mally distributed (as assessed by Kolmogorov-Smirnov and
Shapiro-Wilk tests) andwere presented asmean and standard
deviation and compared by Mann-Whitney 𝑈 or Kruskal
Wallis tests. Nominal data were presented as numbers and
percentages and compared by chi-squared test. The associa-
tion of serum endostatin tertiles (and a 70 ng/mL increase)
with intermittent claudication was assessed using multiple
regression analysis adjusting for age above 76 years (approxi-
mately median age), CHD, hypertension, diabetes, smoking,
stroke, and dyslipidemia.
3. Results
4,248 men attended for blood sampling and assessment
during wave 2 ofHIMS. Samples for endostatinmeasurement
were randomly selected on 1117 men of whom 1114 had
completed the ECQ. Based on ECQ answers, 106 of these
men were defined to have intermittent claudication, 291 had
atypical pain (or could not walk), and 717 had no lower
limb pain. Mean (±standard deviation) serum endostatin
concentrations (ng/mL) were 145.2 ± 106.9 for men with
intermittent claudication, 129.1 ± 79.8 for men with atypical
pain, and 116.3 ± 66.6 for men with no lower limb pain; 𝑃 <
0.001. Men with atypical pain were excluded from further
analysis.
The characteristics of the 106 men with intermittent
claudication and the 717 with no leg pain are shown in
Table 1. Men with intermittent claudication were older and
more likely to have a history of hypertension, diabetes,
dyslipidemia, smoking, CHD, and stroke.
The association of serum endostatin with intermittent
claudication was assessed by adjusting for age above 76 years,
hypertension, diabetes, dyslipidemia, smoking, CHD, and
stroke. Serum endostatin concentration was mildly but sig-
nificantly associated with the presence of intermittent clau-
dication (Table 2). Compared to men with serum endostatin
in the first (<93 ng/mL) tertile, men with serum endostatin
in the second (93–120 ng/mL) tertile had 2.07 adjusted odds
(95% confidence interval 1.15–3.73, 𝑃 = 0.015) of having
intermittent claudication, and men with serum endostatin
in the third (>120 ng/mL) tertile had 1.78 adjusted odds
(95% confidence interval 0.98–3.22, 𝑃 = 0.058) of having
intermittent claudication.
In a further analysis we assessed the association of
a 70 ng/mL increase in endostatin (approximately one
standard deviation) with intermittent claudication after
adjusting for age above 76 years, hypertension, diabetes,
dyslipidemia, smoking, CHD, and stroke. A 70 ng/mL
increase in endostatin was associated with a 1.17-fold rise
in the adjusted odds of having intermittent claudication
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Table 1: Comparison of men with and without intermittent claudication undergoing serum endostatin measurement.
Characteristic Intermittent claudication No intermittent claudication 𝑃 value
Number 106 717
Age (years) 77.9 ± 4.0 76.7 ± 3.6 0.002
Hypertension 70 (66.0%) 296 (41.3%) <0.001
Diabetes mellitus 28 (26.4%) 99 (13.8%) 0.001
Dyslipidemia 75 (70.8%) 325 (45.3%) <0.001
Ever smoker 91 (85.8%) 472 (65.8%) <0.001
Coronary heart disease 58 (54.7%) 193 (26.9%) <0.001
Previous stroke 25 (23.6%) 67 (9.3%) <0.001
Serum endostatin (ng/mL) 145.22 ± 106.93 116.34 ± 66.57 <0.001
Nominal variables are presented as numbers (%) and compared by chi-squared test. Continuous variables are presented as mean (±standard deviation) and
compared by Mann-Whitney 𝑈 test.
Table 2: Independent risk factors for intermittent claudication in
823 men.
Characteristic Odds ratio 95% CI 𝑃 value
Serum endostatin (ng/mL)∗
<93.00 1.00 Reference
93.00–120.00 2.07 1.15–3.73 0.015
>120.00 1.78 0.98–3.22 0.058
Ever smoking 2.59 1.44–4.67 0.002
Previous stroke 2.12 1.22–3.69 0.008
Dyslipidemia 1.96 1.20–3.20 0.007
Coronary heart disease 1.91 1.20–3.05 0.007
Hypertension 1.77 1.11–2.82 0.016
Age above 76 years† 1.67 1.07–2.60 0.023
Diabetes mellitus 1.52 0.90–2.58 0.119
For nominal variables the comparisons are to subjects without the risk
factor. ∗Men with serum endostatin concentrations in the top and middle
tertiles were compared with subjects who had serum endostatin in the lowest
tertile. †Approximately median value. All factors listed were included in the
multivariate model.
(odds ratio 1.17, 95% confidence interval 1.00–1.37, and
𝑃 = 0.050).
4. Discussion
Themain finding of this study was that serum concentrations
of the antiangiogenic protein endostatin were raised in men
with symptoms of intermittent claudication compared to
men who did not have leg pain. This association remained
after adjusting for the cardiovascular risk factors of age,
diabetes, hypertension, and dyslipidemia. We also adjusted
for previous history or treatment of CHD and stroke.
The antiangiogenic effects of endostatin have been of
considerable interest to cancer researchers with a number
of animal model studies suggesting that endostatin admin-
istration inhibits tumour growth [16, 17]. Administration
of recombinant endostatin has also been shown to inhibit
atherosclerotic plaque neovascularization in a rabbit model
[18].These findings raise the possibility that circulating endo-
statin could inhibit angiogenesis and arteriogenesis when
elevated in peripheral artery disease patients and thereby
contribute to the development of lower limb symptoms, such
as intermittent claudication.
Despite the demonstrated ability of endostatin to inhibit
angiogenesis its overall impact on the outcome of vascular
diseases is not yet clear. Studies using a rat model demon-
strated that endostatin was upregulated after myocardial
infarction and that an antiendostatin antibody promoted
mortality [19]. Therefore, in this animal model it is possible
that elevated levels of endostatin occurred in response to
myocardial injury. Furthermore, downregulation of colla-
gen XVIII, which is cleaved to generate endostatin, has
been reported to promote atherosclerosis progression in a
mouse model [20]. Of note recombinant endostatin has
been reported to inhibit atherosclerosis progression in the
same mouse model [21]. Therefore, there are animal data
supporting a beneficial effect of endostatin in the context of
atherosclerosis.
Human data have been derived from observational stud-
ies. Circulating concentrations of endostatin have been found
to be raised in patients with a variety of cancers and in some,
but not all studies, were associated with poor prognosis [22–
25]. Circulating endostatin concentrations have also been
reported to be raised in other diseases including inflam-
matory bowel disease and preeclampsia [26, 27]. Serum
endostatin has also been reported to be increased in patients
with CHD in some studies, emphasizing the importance
of adjusting for this in the current analysis [28, 29]. In
the study of Mitsuma and colleagues the level of serum
endostatin was inversely related to the extent of coronary
collaterals suggesting that endostatin may play a role in
inhibiting collateral formation, in keeping with our results
[28]. In contrast, in the investigation of Iribarren et al.
patients with lower serum endostatin were more at risk of
myocardial infarction [29]. There is no current consensus on
the role of circulating endostatin in vascular disease; however,
the findings of the current study and that of Mitsuma et
al. support the hypothesis that circulating endostatin may
be a marker of impaired collateral formation or reduced
angiogenesis. Further studies on patients with peripheral
artery disease are needed to assess this.
A number of possible limitations of this study should
be considered including sampling error, measurement error,
reverse causality, and residual confounding. While we
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included over 1000men in the current study, the prevalence of
intermittent claudication was low and the generalizability of
the findings to other patients with intermittent claudication,
particularly younger patients and females, is not known.
The assessment of intermittent claudication was limited to
the ECQ. We did not perform other assessments such as
measurement of ankle brachial pressure index or arterial
imaging. It is therefore possible that we incorrectly allo-
cated patients with peripheral artery disease to the control
group. The main aim of our analysis however was to assess
the association of endostatin with symptoms of peripheral
artery disease which we believe are better captured from
the symptom questionnaire than from imaging results. We
corrected for confounding factors which we had assessed in
our analyses, such as CHD, stroke, and cardiovascular risk
factors; however, we were unable to correct for other factors
which may have influenced serum endostatin such as cancer.
The current study is a cross-sectional observational study;
therefore while serum endostatin concentrations were raised
in patients with intermittent claudication we cannot draw
conclusions as to causality.
In conclusion we report for the first time that serum
concentrations of the antiangiogenic protein endostatin are
raised in patients with intermittent claudication. Longitu-
dinal studies are needed to assess the temporal association
between increases in serum endostatin and occurrence of
intermittent claudication using standardized and reliable
diagnostic techniques. Further studies are also needed to
examine the influence of other potential residual confound-
ing factors that were not measured in this study on the asso-
ciation between endostatin and intermittent claudication,
the mechanisms underlying this association, and to clarify
whether endostatin, or its modification, plays a role in the
outcome of peripheral artery disease.
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